Gossamer Bio, Inc.

GOSS
Kuhne v. Gossamer Bio, Inc., No. 3:20-cv-00649 (S.D. Cal.)

The lawsuit alleges violations of both the Securities Act and Securities Exchange Act regarding Gossamer's February 8, 2019 initial public offering. Specifically, Defendants are alleged to have misrepresented the cause of the failure of its phase 2 trial to investors. Defendants are also alleged to have misstated the success of a similar trial by Novartis.

Block & Leviton has been appointed lead plaintiff and anticipates filing an amended complaint.

Lead Plaintiff deadline
class period
February 8, 2019
to
December 13, 2020